Boehringer Ingelheim has strengthened the safety warnings and use precautions for its novel anticoagulant Prazaxa (dabigatran etexilate) in Japan following the deaths of five patients receiving the product. The oral direct thrombin inhibitor, marketed as Pradaxa elsewhere, was the first in the...
